CN1290707A - Nucleoside 5'-thiophosphoryl amino-acid ester compound - Google Patents

Nucleoside 5'-thiophosphoryl amino-acid ester compound Download PDF

Info

Publication number
CN1290707A
CN1290707A CN 00129555 CN00129555A CN1290707A CN 1290707 A CN1290707 A CN 1290707A CN 00129555 CN00129555 CN 00129555 CN 00129555 A CN00129555 A CN 00129555A CN 1290707 A CN1290707 A CN 1290707A
Authority
CN
China
Prior art keywords
compound
nmr
dissolved
thf
1mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 00129555
Other languages
Chinese (zh)
Other versions
CN1133642C (en
Inventor
赵玉芬
苗志伟
韩波
付华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Original Assignee
Tsinghua University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University filed Critical Tsinghua University
Priority to CNB001295551A priority Critical patent/CN1133642C/en
Publication of CN1290707A publication Critical patent/CN1290707A/en
Application granted granted Critical
Publication of CN1133642C publication Critical patent/CN1133642C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Nucleoside 5'-thiiophosphoryl amino acid ester compound is prepared through the processes of dissolving thiophosphoryl trichloride in dried tetrahydrofuran, addition of carbamate hydrochloride through stirring, dripping acid binding agent to react, filtering, rotating distillation to eliminate solvent and other low boiling point matters, hydrolysis in ammonia water and final silica gel chromatography. The compound of the present invention may be used in developing medicine with antiviral, antitumor and HIV resisting activity.

Description

Nucleoside 5 '-thiophosphoryl amino-acid ester compound
The present invention relates to the novel nucleoside 5 '-thiophosphoryl amino-acid ester compound of a class, this compounds has pharmaceutical activitys such as good biological activity and antiviral, antitumor, anti-HIV, can develop into antiviral, antitumor, the anti-HIV prodrug of a kind of ucleosides (prodrugs) in clinical application.
Thiophosphoric acid contains the structure that a sulphur replaces oxygen on phosphorus atom, though this structure is still keeping original electric charge, the character that is keeping highly water-soluble, but other physicochemical properties of the dna oligo of thiophosphoric acid (S-oligos) and biology attribute all have very big difference with natural phosphodiester prototype.One of marked difference is that thiophosphoric acid has resistivity to nuclease.Because the phosphodiester class antisense oligonucleotide that adds has been fallen in the existence of exonuclease in the cell, very fast digestion, make its forfeiture action function.
The objective of the invention is to develop a class nucleosides-thiophosphoryl amino acid ester compound, by synthetic thiophosphoric acid compounds with opposing nuclease, synthetic dna oligo is to be used to develop antiviral, antitumor, HIV (human immunodeficiency virus)-resistant activity medicine.
Total following four kinds of the nucleoside 5 '-thiophosphoryl amino-acid ester compound of the present invention's preparation,
Wherein first kind is adenosine 5 '-thiophosphoryl amino acid ester compound, and its structural formula is:
Figure 0012955500041
R is H in the said structure formula, CH 3, C 6H 5CH 2, (CH 3) 2CH 2, (CH 3) 2CHCH 2
The synthesis step of above-claimed cpd: 1) under nitrogen protection, room temperature (25 ℃) is dissolved in phosphorus thiochloride in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.2) the amino acid methyl ester hydrochloride of adding same substance amount in above-mentioned solution slowly drips acid binding agent (as triethylamine, the N-Methylimidazole) after stirring.3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the adenosine that is dissolved in the dry pyridine is slowly splashed in the above-mentioned system, acid binding agent is continued to drip in the back that stirs.4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.5) after the hydrolysis fully, carry out column chromatography for separation, can obtain product with silicagel column.
Second kind of compound wherein is guanosine 5 '-thiophosphoryl amino acid ester compound, and its structural formula is:
Figure 0012955500042
R is H in the said structure formula, CH 3, C 6H 5CH 2, (CH 3) 2CH 2, (CH 3) 2CHCH 3
The synthesis step of above-claimed cpd:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in phosphorus thiochloride in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) the amino acid methyl ester hydrochloride of the amount of adding same substance in above-mentioned solution slowly drips acid binding agent (as triethylamine, the N-Methylimidazole) after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the guanosine that is dissolved in the dry pyridine is slowly splashed in the above-mentioned system, acid binding agent is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation, can obtain product with silicagel column.
The third compound wherein is cytidine 5 '-thiophosphoryl amino acid ester compound, and its structural formula is:
R is H in the said structure formula, CH 3, C 6H 5CH 2, (CH 3) 2CH 2, (CH 3) 2CHCH 2
The synthesis step of above-claimed cpd:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in phosphorus thiochloride in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) the amino acid methyl ester hydrochloride of the amount of adding same substance in above-mentioned solution slowly drips acid binding agent (as triethylamine, the N-Methylimidazole) after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the cytidine that is dissolved in the dry pyridine is slowly splashed in the above-mentioned system, acid binding agent is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation, can obtain product with silicagel column.
The 4th kind of compound wherein is uridine 5 '-thiophosphoryl amino acid ester compound, and its structural formula is:
R is H in the said structure formula, CH 3, C 6H 5CH 2, (CH 3) 2CH 2, (CH 3) 2CHCH 2
The synthesis step of above-claimed cpd:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in phosphorus thiochloride in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) the amino acid methyl ester hydrochloride of the amount of adding same substance in above-mentioned solution slowly drips acid binding agent (as three second peace, N-Methylimidazole) after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the uridine that is dissolved in the dry THF is slowly splashed in the above-mentioned system, acid binding agent is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation, can obtain product with silicagel column.
The anti-HIV-1 activity experiment of above-mentioned synthetic series compound in cem cell and MT-4 cell finds all to have activity in various degree, can be used to develop antiviral, antitumor, HIV (human immunodeficiency virus)-resistant activity medicine.
Below be embodiments of the invention:
Embodiment 1: the preparation of adenosine 5 '-thiophosphoryl glycine methyl ester compound, wherein R is H.
The structural formula of compound:
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the glycine methyl ester hydrochloride of 1mmol (0.125g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the adenosine that 1mmol (0.267g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product adenosine 5 '-thiophosphoryl glycine methyl ester at 16.5: 1: 1, productive rate is 68.4%.Spectral data is as follows: 31P NMR (DMSO-d 6, δ: ppm, J:Hz): δ 59.38,58.62; 1H NMR (500MHz, DMSO-d 6): δ 9.26,9.22 (bs, 1H, NH), 8.43 (1H, s, H-2), 8.23 (1H, s, H-8), 7.40 (2H, s, NH 2), 6.44 (1H, m, H-1 '), 4,50 (2H, m, H-2 ', 3 '), 3.97 (1H, m, H-4 '), 3.88 (3H, s,
OCH 3)，3．64(2H，m，H-5′)，3．57(2H，m，H-α)； 13C?NMR(500MHz，DMSO-d 6)：δ173．24(COOMe)，163．70(C-2)，150．43(C-4)，140．76(C-6)，101．76(C-1′)，87．74(C-5)，84．83(C-2′)，73．54(C-3′)，69．80(C-4′)，60．87(C-5′)，54．78(OCH 3)，45．86(C-α)；ESI-MS(pos．)：m／z?435(M+H) +；ESI-MS(neg．)：m/z?433(M-H) -。The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
HIV=Human?immunodeficiency?virus
MT-4=Human?leukenia?T?cell
CEM=Human?lymphoblastoid?T?cell
ED 50=antiviral activity index
CD 50=cytotoxicity index
ED 50 CEM-TK- 5×10 -4M (CD 50?7×10 -6M)
CEM-SS 4×10 -3M (CD 50?9×10 -5M)
MT?4 2×10 -1M (CD 50 8×10 -6M)
Embodiment 2: the preparation of adenosine 5 '-thiophosphoryl alanine methyl ester compound, wherein R is CH3.The structural formula of compound:
Figure 0012955500071
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the alanine methyl ester hydrochloride of 1mmol (0.14g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the adenosine that 1mmol (0.267g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product adenosine 5 '-thiophosphoryl alanine methyl ester at 16.5: 1: 1, productive rate is 66.4%.Spectral data is as follows: 31P NMR (DMSO-d 6, δ: ppm, J:Hz): δ 59.86,58.53; 1H NMR (500MHz, DMSO-d 6): δ 9.44,9.40 (bs, 1H, NH), 8.89 (1H, s, H-2), 8.67 (1H, s, H-8), 7.67 (2H, s, NH 2), 6.59 (1H, m, H-1 '), 4,78 (2H, m, H-2 ', 3 '), 4.22 (1H, m, H-4 '), 3.98 (3H, s, OCH 3), 3.85 (2H, m, H-5 '), 3.67 (2H, m, H-α), 1.31,1.30 (3H, d, 3J=6, β-CH 3); 13C NMR (500MHz, DMSO-d 6): δ 180.24 (COOMe), 170.70 (C-2), 156.43 (C-4), l49.76 (C-6), (108.23 C-1 '), 89.66 (C-5), 85.87 (C-2 '), 76.23 (C-3 '), (69.66 C-4 '), 61.23 (C-5 '), 54.78 (OCH 3), 50.73 (C-α), 48.66 (C-β); ESI-MS (pos.): m/z 449 (M+H) +ESI-MS (neg.): m/z 447 (M-H) -The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 8×10 -3M (CD 50 3×10 -6M)
CEM-SS 6×10 -3M (CD 50 9×10 -5M)
MT?4 8×10 -4M (CD 50 6×10 -6M)
Embodiment 3: the preparation of adenosine 5 '-thiophosphoryl phenylalanine methyl ester compound, wherein R is C 6H 5CH 2The structural formula of compound:
Figure 0012955500072
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the phenylalanine methyl ester hydrochloride of 1mmol (0.22g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the adenosine that 1mmol (0.267g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product adenosine 5 '-thiophosphoryl phenylalanine methyl ester at 16.5: 1: 1, productive rate is 69.7%.Spectral data is as follows: 31P NMR (DMSO-d 6, δ: ppm, J:Hz): δ 60.64,60.33; 1H NMR (500MHz, DMSO-d 6): δ 9.21,9.15 (bs, 1H, NH), 8.67 (1H, s, H-2), 8.58 (1H, s, H-8), 7.88 (2H, s, NH 2), 7.15-7.35 (5H, m, Ph), 6.59 (1H, m, H-1 '), 4,55 (2H, m, H-2 ', 3 '), 4.37 (1H, m, H-4 '), 3.79 (3H, s, OCH 3), 3.66 (2H, m, H-5 '), 3.48 (2H, m, H-α), 2.32 (2H, m, H-β); 13C NMR (500MHz, DMSO-d 6): δ 174.24 (COOMe), 170.60 (C-2), 159.43 (C-4), 148.36 (Ph-Jpso), 136.11 (C-6), 135.12 (Ph-para), 130.42 (Ph-ortho), 119.91 (Ph-meta), 108.23 (C-1 '), 89.65 (C-5), 87.87 (C-2 '), 76.23 (C-3 '), (72.66 C-4 '), (61.23 C-5 '), 56.82 (C-β), 56.78 (OCH 3), 52.73 (C-α); ESI-MS (pos.): m/z 527 (M+H) +ESI-MS (neg.): m/z 525 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 8×10 -2M (CD 50 4×10 -5M)
CEM-SS 9×10 -3M (CD 50 4×10 -6M)
MT?4 6×10 -5M (CD 50 5×10 -6M)
Embodiment 4: the preparation of adenosine 5 '-thiophosphoryl valine methyl ester compound, wherein R is (CH 3) 2CHCH.
The structural formula of compound:
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the valine methyl ester hydrochloride of 1mmol (0.17g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the adenosine that 1mmol (0.267g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product adenosine 5 '-thiophosphoryl valine methyl ester at 16.5: 1: 1, productive rate is 59.2%.Spectral data is as follows: 31P NMR (DMSO-d 6, δ: ppm, J:Hz): δ 56.32,56.14; 1H NMR (500MHz, DMSO-d 6): δ 9.44,9.40 (bs, 1H, NH), 8.67 (1H, s, H-2), 8.58 (1H, s, H-8), 7.54 (2H, s, NH 2), 6.59 (1H, m, H-1 '), 4,78 (2H, m, H-2 ', 3 '), 4.22 (1H, m, H-4 '), 3.98 (3H, s, OCH 3), 3.85 (2H, m, H-5 '), 3.67 (1H, m, H-α), 3.45 (1H, m, H-β), 1.61 (3H, s, CH 3), 1.42 (3H, s, CH 3); 13C NMR (500MHz, DMSO-d 6): δ 172.24 (COOMe), 165.70 (C-2), 159.43 (C-4), 145.76 (C-6), (108.23 C-1 '), 89.66 (C-5), 85.87 (C-2 '), 76.23 (C-3 '), (69.66 C-4 '), 61.23 (C-5 '), 54.78 (OCH 3), 50.73 (C-α), 48.66 (C-β), 26.40 (CH 3), 26.86 (CH 3); ESI-MS (pos.): m/z 518 (M+H) +ESI-MS (neg.): m/z 516 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 7×10 -3M (CD 50 8×l0 -6M)
CEM-SS 6×10 -3M (CD 50 5×10 -6M)
MT?4 8×10 -4M (CD 50 6×10 -5M)
Embodiment 5: the preparation of adenosine 5 '-thiophosphoryl leucine methyl compound, wherein R is (CH 3) 2CHCH 2
The structural formula of compound:
The synthesis step of compound
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the leucine methyl ester hydrochloride of 1mmol (0.18g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the adenosine that 1mmol (0.267g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product adenosine 5 '-thiophosphoryl leucine methyl esters at 16.5: 1: 1, productive rate is 65.2%.Spectral data is as follows: 31P NMR (DMSO-d 6, δ: ppm, J:Hz): δ 58.32,57.68; 1H NMR (500MHz, DMSO-d 6): δ 9.31,9.27 (bs, 1H, NH), 8.67 (1H, s, H-2), 8.58 (1H, s, H-8), 7.54 (2H, s, NH 2), 6.59 (1H, m, H-1 '), 4,78 (2H, m, H-2 ', 3 '), 4.22 (1H, m, H-4 '), 3.98 (3H, s, OCH 3), 3.85 (2H, m, H-5 '), 3.67 (1H, m, H-α), 3.45 (1H, m, H-β), 3.21 (1H, m, H-γ), 1.61 (3H, s, CH 3), 1.42 (3H, s, CH 3); 13C NMR (500MHz, DMSO-d 6): δ 172.24 (COOMe), 165.70 (C-2), 159.43 (C-4), 145.76 (C-6), (109.23 C-1 '), 89.66 (C-5), 85.87 (C-2 '), 76.23 (C-3 '), (69.66 C-4 '), 61.23 (C-5 '), 54.78 (OCH 3), 50.73 (C-α), 48.66 (C-β), 46.35 (C-γ); ESI-MS (pos.): m/z 492 (M+H) +ESI-MS (neg.): m/z 490 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 5×10 -4M (CD 50 2×10 -6M)
CEM-SS 2×10 -4M (CD 50 5×10 -5M)
MT?4 5×10 -3M (CD 50 8×10 -6M)
Embodiment 6: the preparation of guanosine 5 '-thiophosphoryl glycine methyl ester compound, wherein R is H.
The structural formula of compound:
Figure 0012955500101
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the glycine methyl ester hydrochloride of 1mmol (0.125g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the guanosine that 1mmol (0.283g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product guanosine 5 '-thiophosphoryl glycine methyl ester at 16.5: 1: 1, productive rate is 63.4%.
Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 57.68,57.39; 1H NMR (500MHz, D 2O): δ 8.18 (1H, s, H-8), 5.82,5.81 (1H, d, 3J=6.0, H-1 '), 4,89 (1H, m, H-2 '), 4.23 (1H, m, H-3 '), 3.23 (1H, m, H-4 '), 3.54 (3H, s, OCH 3), 3.65 (2H, m, H-5 '), 3.54 (2H, m, H-α), 1.66,1.65 (3H, d, 3J=6.0, β-CH 3); 13C NMR (500MHz, D 2O): δ 172.31 (COOMe), 165.81 (C-2), 158.67 (C-6), 152.34 (C-4), 139.66 (C-8), 118.71 (C-5), 89.42 (C-4 '), 86.25 (C-1 '), (73.55 C-3 '), 70.82 (C-2 '), 61.45 (C-5 '), 54.62 (OCH 3), 50.62 (C-β), 45.89 (C-α); ESI-MS (pos.): m/z 451 (M+H) +ESI-MS (neg.): m/z 449 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 8×10 -4M (CD 50 6×10 -5M)
CEM-SS 3×10 -4M (CD 50 4×10 -6M)
MT?4 6×10 -4M (CD 50 3×10 -5M)
Embodiment 7: the preparation of guanosine 5 '-thiophosphoryl alanine methyl ester compound, wherein R is CH 3
The structural formula of compound:
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the alanine methyl ester hydrochloride of 1mmol (0.140g), slowly drip 2mmol (0.2g) triethylamine after stirring.
4) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the guanosine that 1mmol (0.283g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
5) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
6) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product guanosine 5 '-thiophosphoryl alanine methyl ester at 16.5: 1: 1, productive rate is 65.3%.
Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 58.88,58.37; 1H NMR (500MHz, D 2O): δ 8.07 (1H, s, H-8), 5.82,5.81 (1H, d, 1J=6.0, H-1 '), 4,51 (1H, m, H-2 '), 4.18 (1H, m, H-3 '), 3.94 (1H, m, H-4 '), 3.86 (3H, s, OCH 3), 3.68 (2H, m, H-5 '), 3.57 (2H, m, H-α); 13C NMR (500MHz, D 2O): δ 178.31 (COOMe), 156.81 (C-2), 153.67 (C-6), 151.34 (C-4), 135.66 (C-8), 116.71 (C-5), 86.42 (C-4 '), 85.25 (C-1 '), (73.74 C-3 '), 70.42 (C-2 '), 61.45 (C-5 '), 54.62 (OCH 3), 45.89 (C-α); ESI-MS (pos.): m/z 466 (M+H) +ESI-MS (neg.): m/z 464 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 6×10 -4M (CD 50 7×10 -5M)
CEM-SS 9×10 -3M (CD 50 6×10 -5M)
MT?4 2×10 -4M (CD 50 8×10 -5M)
Embodiment 8: the preparation of guanosine 5 '-thiophosphoryl phenylalanine methyl ester compound, wherein R is C 6H 5CH 2
The structural formula of compound:
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the phenylalanine methyl ester hydrochloride of 1mmol (0.21g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the guanosine that 1mmol (0.283g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product guanosine 5 '-thiophosphoryl phenylalanine methyl ester at 16.5: 1: 1, productive rate is 70.3%.Spectral data is as follows: 31P NMR (D 2O, δ: ppm.J:Hz): δ 57.18,56.89; 1H NMR (500MHz, D 2O): δ 8.07 (1H, s, H-8), 7.25-7.41 (5H, m, Ph), 5.79,5.78 (1H, d, 3J=6.0, H-1 '), 4,41 (1H, m, H-2 '), 4.18 (1H, m, H-3 '), 3.94 (1H, m, H-4 '), 3.86 (3H, s, OCH 3), 3.68 (2H, m, H-5 '), 3.57 (2H, m, H-α), 2.27 (2H, m, H-β); 13C NMR (500MHz, D 2O): δ 180.31 (COOMe), 166.81 (C-2), 161.67 (C-6), 158.34 (C-4), 151.26 (Ph-jpso), 135.66 (C-8), 130.07 (Ph-para), 128.23 (Ph-ortho), 118.45 (Ph-meta), 96.71 (C-5), 86.42 (C-4 '), 85.25 (C-1 '), (73.74 C-3 '), 70.42 (C-2 '), 61.45 (C-5 '), (57.22 C-β), 54.62 (OCH 3), 45.89 (C-α); ESI-MS (pos.): m/z 541 (M+H) +ESI-MS (neg.): m/z 539 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 8×10 -3M (CD 50 6×10 -5M)
CEM-SS 6×10 -4M (CD 50 5×10 -5M)
MT?4 2×10 -4M (CD 50 8×10 -5M)
Embodiment 9: the preparation of guanosine 5 '-thiophosphoryl valine methyl ester compound, wherein R is (CH 3) 2CH.
The structural formula of compound:
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the alanine methyl ester hydrochloride of 1mmol (0.170g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the guanosine that 1mmol (0.283g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product guanosine 5 '-thiophosphoryl valine methyl ester at 16.5: 1: 1, productive rate is 66.2%.
Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 59.86,59.27; 1H NMR (500MHz, D 2O): δ 9.07 (1H, s, H-8), 6.82,6.81 (1H, d, 3J=6.0, H-1 '), 5,48 (1H, m, H-2 '), 4.95 (1H, m, H-3 '), 4.36 (1H, m, H-4 '), 3.86 (3H, s, OCH 3), 3.68 (2H, m, H-5 '), 3.57 (2H, m, H-α), 3.45 (1H, m, H-β), 1.16,1.15 (3H, d, 3J=6.0, CH 3), 1.06,1.05 (3H, d, 3J=6.0, CH 3); 13C NMR (500MHz, D 2O): δ 178.31 (COOMe), 156.81 (C-2), 153.67 (C-6), 151.34 (C-4), 135.66 (C-8), 116.71 (C-5), 86.42 (C-4 '), 85.25 (C-1 '), (73.74 C-3 '), 70.42 (C-2 '), 61.45 (C-5 '), 54.62 (OCH 3), 45.89 (C-α), 44.24 (C-β), 23.66 (CH 3), 23.15 (CH 3); ESI-MS (pos.): m/z 493 (M+H) +ESI-MS (neg.): m/z 491 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 5×10 -3M (CD 50 3×10 -5M)
CEM-SS 5×10 -3M (CD 50 8×10 -5M)
MT?4 4×10 -3M (CD 50 6×10 -5M)
Embodiment 10: the preparation of guanosine 5 '-thiophosphoryl leucine methyl compound, wherein R is (CH 3) 2CHCH 2
The structural formula of compound:
Figure 0012955500131
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the leucine methyl ester hydrochloride of 1mmol (0.180g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the guanosine that 1mmol (0.283g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product guanosine 5 '-thiophosphoryl leucine methyl esters at 16.5: 1: 1, productive rate is 62.2%.Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 58.86,58.27; 1H NMR (500MHz, D 2O): δ 9.07 (1H, s, H-8), 6.82,6.81 (1H, d, 3J=6.0, H-1 '), 5,48 (1H, m, H-2 '), 4.95 (1H, m, H-3 '), 4.36 (1H, m, H-4 '), 3.86 (3H, s, OCH 3), 3.68 (2H, m, H-5 '), 3.57 (2H, m, H-α), 3.45 (1H, m, H-β), 3.22 (1H, m, H-γ), 1.16,1.15 (3H, d, 3J=6.0, CH 3), 1.06,1.05 (3H, d, 3J=6.0, CH 3); 13C NMR (500MHz, D 2O): δ 178.31 (COOMe), 166.81 (C-2), 159.67 (C-6), 156.34 (C-4), 134.66 (C-8), 116.71 (C-5), 86.42 (C-4 '), 85.25 (C-1 '), (73.74 C-3 '), 70.42 (C-2 '), 61.45 (C-5 '), 54.62 (OCH 3), 45.89 (C-α), 44.24 (C-β), 41.24 (C-γ); ESI-MS (pos.): m/z 508 (M+H) +ESI-MS (neg.): m/z 506 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 6×10 -4M (CD 50 6×10 -5M)
CEM-SS 6×10 -4M (CD 50 5×10 -5M)
MT?4 8×10 -4M (CD 50 7×10 -5M)
Embodiment 11: the preparation of cytidine 5 '-thiophosphoryl glycine methyl ester compound, wherein R is H.
The structural formula of compound:
Figure 0012955500141
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the glycine methyl ester hydrochloride of 1mmol (0.125g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the cytidine that 1mmol (0.242g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product cytidine 5 '-thiophosphoryl glycine methyl ester at 16.5: 1: 1, productive rate is 61.4%.
Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 57.88,56.16; 1H NMR (500MHz, D 2O): δ 7.90,7.89 (1H, d, 3J=5.5, H-6), 6.24 (1H, m, H-1 '), 5.84,5.83 (1H, d, 3J=6, H-5), 4.28 (1H, m, H-3 '), 3.88 (1H, m, H-4 '), 3.71 (3H, s, OCH 3), 3.65 (2H, m, H-5 '), 2.69 (2H, m, H-α), 2.15 (1H, H-2 '); 13C NMR (500MHz, D 2O): δ 177.63 (COOMe), 165.82 (C-4), 158.13 (C-2), 140.34 (C-6), 93.71 (C-5), 87.25 (C-1 '), 84.42 (C-4 '), 70.42 (C-3 '), 61.45 (C-5 '), 54.62 (OCH 3), 45.89 (C-α), 39.82 (C-2 '); ESI-MS (pos.): m/z 411 (M+H) +ESI-MS (neg.): m/z 409 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 8×10 -4M (CD 50 6×10 -5M)
CEM-SS 6×10 -3M (CD 50 4×10 -5M)
MT?4 6×10 -4M (CD 50 3×10 -6M)
Embodiment 12: the preparation of cytidine 5 '-thiophosphoryl alanine methyl ester compound, wherein R is CH 3
The structural formula of compound:
Figure 0012955500142
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the alanine methyl ester hydrochloride of 1mmol (0.14g), slowly drip 2mmol (0.2g) triethylamine after stirring.
4) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the cytidine that 1mmol (0.242g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
5) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
6) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product cytidine 5 '-thiophosphoryl alanine methyl ester at 16.5: 1: 1, productive rate is 68.4%.Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 57.66,57.31; 1H NMR (500MHz, D 2O): δ 7.90,7.89 (1H, d, 3J=5.5, H-6), 6.88 (1H, m, H-1 '), 5.84,5.83 (1H, d, 3J=6, H-5), 4.68 (1H, m, H-3 '), 3.88 (1H, m, H-4 '), 3.71 (3H, s, OCH 3), 3.65 (2H, m, H-5 '), 2.89 (2H, m, H-α), 2.66 (1H, H-2 '), 1.45 (3H, d, 3J=6, H-β); 13C NMR (500MHz, D 2O): δ 185.63 (COOMe), 165.82 (C-4), 158.13 (C-2), 145.34 (C-6), 93.71 (C-5), 87.25 (C-1 '), 84.42 (C-4 '), 70.42 (C-3 '), 61.45 (C-5 '), 54.62 (OCH 3), 50.86 (C-β), 45.89 (C-α), 39.82 (C-2 '); ESI-MS (pos.): m/z 424 (M+H) +ESI-MS (neg.): m/z 422 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 5×10 -3M (CD 50 5×10 -5M)
CEM-SS 5×10 -3M (CD 50 8×10 -6M)
MT?4 7×10 -4M (CD 50 3×10 -6M)
Embodiment 13: the system of cytidine 5 '-thiophosphoryl phenylalanine methyl ester compound is put forth energy, and wherein R is C 6H 5CH 2
The structural formula of compound:
Figure 0012955500151
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the phenylalanine methyl ester hydrochloride of 1mmol (0.22g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the cytidine that 1mmol (0.242g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product cytidine 5 '-thiophosphoryl phenylalanine methyl ester at 16.5: 1: 1, productive rate is 66.7%.
Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 58.71,58.13; 1H NMR (500MHz, D 2O): δ 8.22,8.21 (1H, d, 3J=5.5, H-6), 7.29-7.41 (5H, m, Ph), 7.03 (1H, m, H-1 '), 5.84,5.83 (1H, d, 3J=6, H-5), 4.66 (1H, m, H-3 '), 3.82 (1H, m, H-4 '), 3.58 (3H, s, OCH 3), 3.44 (2H, m, H-5 '), 2.89 (2H, m, H-α), 2.66 (1H, H-2 '), 2.27 (1H, m, H-β); 13C NMR (500MHz, D 2O): δ 180.63 (COOMe), 165.82 (C-4), 158.13 (C-2), 146.36 (Ph-jpso), 117.02,136.11 (C-6), 137.12 (Ph-para), 136.42 (Ph-ortho), 122.91 (Ph-meta), 93.71 (C-5), (87.25 C-1 '), 84.42 (C-4 '), 70.42 (C-3 '), (61.45 C-5 '), 54.62 (OCH 3), 50.86 (C-β), 45.89 (C-α), 39.82 (C-2 '); ESI-MS (pos.): m/z 500 (M+H) +ESI-MS (neg.): m/z 498 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 5×10 -4M (CD 50 8×10 -5M)
CEM-SS 6×10 -4M (CD 50 8×10 -5M)
MT?4 8×10 -4M (CD 50 7×10 -5M)
Embodiment 14: the preparation of cytidine 5 '-thiophosphoryl valine methyl ester compound, wherein R is (CH 3) 2CH.
The structural formula of compound:
Figure 0012955500161
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the valine methyl ester hydrochloride of 1mmol (0.17g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the cytidine that 1mmol (0.242g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product cytidine 5 '-thiophosphoryl valine methyl ester at 16.5: 1: 1, productive rate is 63.4%.Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 59.98,59.21; 1H NMR (500MHz, D 2O): δ 7.90,7.89 (1H, d, 3J=5.5, H-6), 6.63 (1H, m, H-1 '), 5.84,5.83 (1H, d, 3J=6, H-5), 4.61 (1H, m, H-3 '), 3.69 (1H, m, H-4 '), 3.76 (3H, s, OCH 3), 3.65 (2H, m, H-5 '), 2.89 (2H, m, H-α), 2.66 (1H, H-2 '), 2.14 (1H, m, H-β); 13C NMR (500MHz, D 2O): δ 185.63 (COOMe), 165.82 (C-4), 158.13 (C-2), 145.34 (C-6), 93.71 (C-5), 87.25 (C-1 '), 84.42 (C-4 '), 70.42 (C-3 '), 61.45 (C-5 '), 54.62 (OCH 3), 50.86 (C-β), 49.89 (C-α), 46.21 (C-β), 39.82 (C-2), ESI-MS (pos.): m/z 466 (M+H) +ESI-MS (neg.): m/z 464 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 5×10 -4M (CD 50 5×10 -5M)
CEM-SS 5×10 -4M (CD 50 9×10 -5M)
MT?4 8×10 -3M (CD 50 3×10 -5M)
Embodiment 15: the preparation of cytidine 5 '-thiophosphoryl leucine methyl compound, wherein R is (CH 3) 2CHCH 2
The structural formula of compound:
Figure 0012955500171
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the leucine methyl ester hydrochloride of 1mmol (0.18g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the cytidine that 1mmol (0.242g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product cytidine 5 '-thiophosphoryl leucine methyl esters at 16.5: 1: 1, productive rate is 65.4%.Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 56.36,56.56; 1H NMR (500MHz, D 2O): δ 7.96,7.95 (1H, d, 3J=6, H-6), 6.36 (1H, m, H-1 '), 5.84,5.83 (1H, d, 3J=6, H-5), 4.78 (1H, m, H-3 '), 3.88 (1H, m, H-4 '), 3.76 (3H, s, OCH 3), 3.65 (2H, m, H-5 '), 3.22 (2H, m, H-α), 2.96 (1H, H-2 '), 2.77 (1H, m, H-β), 2.39 (1H, m, H-γ); 13C NMR (500MHz, D 2O): δ 185.63 (COOMe), 165.82 (C-4), 158.13 (C-2), 145.34 (C-6), 93.71 (C-5), 88.25 (C-1 '), 85.42 (C-4 '), 70.42 (C-3 '), 61.45 (C-5 '), 54.88 (OCH 3), 50.86 (C-β), 48.89 (C-α), 46.21 (C-γ), 39.82 (C-2 '); ESI-MS (pos.): m/z 468 (M+H) +ESI-MS (neg.): m/z 466 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 5×10 -3M (CD 50 6×10 -6M)
CEM-SS 8×10 -3M (CD 50 9×10 -6M)
MT?4 7×10 -3M (CD 50 8×10 -6M)
Embodiment 16: the preparation of uridine 5 '-thiophosphoryl glycine methyl ester compound, wherein R is H.
The structural formula of compound:
Figure 0012955500181
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the glycine methyl ester hydrochloride of 1mmol (0.125g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the uridine that 1mmol (0.244g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product uridine 5 '-thiophosphoryl glycine methyl ester at 16.5: 1: 1, productive rate is 68.4%.Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 57.68,56.89; 1H NMR (500MHz, D 2O): δ 7.79,7.78 (1H, dd, 3J=4.5, H-6), 5.82 (2H, m, H-1 ', 5), 4.93 (2H, m, H-2 ', 3 '), 4.52 (1H, m, H-4 '), 4.00 (2H, m, H-5 '), 3.63 (3H, s, OCH 3), 3.57 (2H, m, H-α); 13C NMR (500MHz, D 2O): δ 177.08 (COOMe), 169.02 (C-4), 153.99 (C-2), 145.39,145.36 (C-6), 104.33,104.22 (C-5), 95.83,95.16 (C-1 '), (87.97 C-4 '), 87.20,87.13 (C-2 '), 83.64, (83.51 C-3 '), 67.24 (C-5 '), 55.09 (OCH 3), 45.80,45.73 (C-α); ESI-MS (pos.): m/z 413 (M+H) +ESI-MS (neg.): m/z 411 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 8×10 -3M (CD 50 9×10 -5M)
CEM-SS 9×10 -3M (CD 50 8×10 -5M)
MT?4 8×10 -4M (CD 50 5×10 -6M)
Embodiment 17: the preparation of uridine 5 '-thiophosphoryl alanine methyl ester compound, wherein R is CH 3
The structural formula of compound:
Figure 0012955500182
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the alanine methyl ester hydrochloride of 1mmol (0.14g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the uridine that 1mmol (0.244g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product uridine 5 '-thiophosphoryl alanine methyl ester at 16.5: 1: 1, productive rate is 71.4%.Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 58.32,57.68; 1H NMR (500MHz, D 2O): δ 7.88,7.87 (1H, dd, 3J=5, H-6), 5.89 (2H, m, H-1 ', 5), 4.98 (2H, m, H-2 ', 3 '), 4.61 (1H, m, H-4 '), 4.04 (2H, m, H-5 '), 3.73 (3H, s, OCH 3), 3.57 (2H, m, H-α), 1.31,1.30 (3H, d, 3J=6, β-CH 3); 13C NMR (500MHz, D 2O): δ 175.04 (COOMe), 166.73 (C-4), 149.28 (C-2), 144.36,144.32 (C-6), 107.62,107.43 (C-5), 98.76,98.41 (C-1 '), (86.23 C-4 '), 85.71,85.63 (C-2 '), 82.70, (82.58 C-3 '), 65.44 (C-5 '), 56.87 (OCH 3), 50.73 (C-α), 48.66 (C-β); ESI-MS (pos.): m/z 426 (M+H) +ESI-MS (neg.): m/z 424 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 8×10 -4M (CD 50 6×10 -5M)
CEM-SS 7×10 -4M (CD 50 6×10 -5M)
MT?4 8×10 -4M (CD 50 5×10 -5M)
Embodiment 18: the preparation of uridine 5 '-thiophosphoryl phenylalanine methyl ester compound, wherein R is C 6H 5CH 2
The structural formula of compound:
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the phenylalanine methyl ester hydrochloride of 1mmol (0.21g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (1NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the uridine that 1mmol (0.244g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product uridine 5 '-thiophosphoryl phenylalanine methyl ester at 16.5: 1: 1, productive rate is 72.4%.Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 60.32,59.68; 1H NMR (500MHz, D 2O): δ 7.88,7.87 (1H, dd, 3J=5, H-6), 7.22-7.46 (5H, m, Ph), 6.08 (2H, m, H-1 ', 5), 5.15 (2H, m, H-2 ', 3 '), 4.71 (1H, m, H-4 '), 4.34 (2H, m, H-5 '), 3.93 (3H, s, OCH 3), 3.57 (2H, m, H-α), 2.37 (2H, m, H-β); 13C NMR (500MHz, D 2O): δ 178.04 (COOMe), 166.73 (C-4), 149.28 (C-2), 148.39 (Ph-jpso), 148.36,148.32 (C-6), 139.12 (Ph-para), 129.42 (Ph-ortho), 122.91 (Ph-meta), 110.62,110.43 (C-5), 98.76,98.41 (C-1 '), 88.23 (C-4 '), 85.71,85.63 (C-2 '), 83.27, (82.58 C-3 '), 65.44 (C-5 '), 56.87 (OCH 3), 50.73 (C-α), 48.66 (C-β); ESI-MS (pos.): m/z 522 (M+H) +ESI-MS (neg.): m/z 520 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 8×10 -4M (CD 50 7×10 -5M)
CEM-SS 7×10 -4M (CD 50 6×10 -5M)
MT?4 6×10 -4M (CD 50 6×10 -5M)
Embodiment 19: the preparation of uridine 5 '-thiophosphoryl valine methyl ester compound, wherein R is (CH 3) 2CH.
The structural formula of compound:
Figure 0012955500201
The synthesis step of compound
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the valine methyl ester hydrochloride of 1mmol (0.14g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the uridine that 1mmol (0.244g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product uridine 5 '-thiophosphoryl valine methyl ester at 16.5: 1: 1, productive rate is 65.4%.Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 58.32,57.55; 1H NMR (500MHz, D 2O): δ 7.89,7.88 (1H, dd, 3J=5, H-6), 5.99 (2H, m, H-1 ', 5), 4.96 (2H, m, H-2 ', 3 '), 4.61 (1H, m, H-4 '), 4.04 (2H, m, H-5 '), 3.73 (3H, s, OCH 3), 3.57 (2H, m, H-α), 3.45 (1H, m, H-β), 1.31,1.30 (2H, d, 2CH 3); 13C NMR (500MHz, D 2O): δ 178.04 (COOMe), 167.55 (C-4), 146.28 (C-2), 144.36,144.32 (C-6), 107.62,107.43 (C-5), 98.76,98.41 (C-1 '), (86.23 C-4 '), 85.71,85.63 (C-2 '), 82.70, (82.58 C-3 '), 65.44 (C-5 '), 56.87 (OCH 3), 50.73 (C-α), 48.66 (C-β), 22.45 (CH 3), 22.55 (CH 3); ESI-MS (pos.): m/z 454 (M+H) +ESI-MS (neg.): m/z 452 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 9×10 -3M (CD 50 8×10 -5M)
CEM-SS 6×10 -3M (CD 50 8×10 -5M)
MT?4 8×10 -4M (CD 50 2×10 -5M)
Embodiment 20: the preparation of uridine 5 '-thiophosphoryl leucine methyl compound, wherein R is (CH 3) 2CHCH 2
The structural formula of compound:
Figure 0012955500211
The synthesis step of compound:
1) under nitrogen protection, room temperature (25 ℃) is dissolved in the phosphorus thiochloride of 1mmol (0.17g) in the dry tetrahydrofuran (THF) of crossing (THF), is mixed with the solution of 1mol/L.
2) in above-mentioned solution, add the leucine methyl ester hydrochloride of 1mmol (0.18g), slowly drip 2mmol (0.2g) triethylamine after stirring.
3) follow the tracks of reaction process with nuclear magnetic resonance analyser (NMR), treat that the phosphorus thiochloride total overall reaction finishes after, the uridine that 1mmol (0.244g) has been dissolved in the dry pyridine slowly splashes in the above-mentioned system, 1mmol (0.1g) triethylamine is continued to drip in the back that stirs.
4) finish with the NMR monitoring reaction after, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last.
5) after the hydrolysis fully, carry out column chromatography for separation with silicagel column, eluent is a Virahol: ammoniacal liquor: water=can obtain product uridine 5 '-thiophosphoryl leucine methyl esters at 16.5: 1: 1, productive rate is 67.5%.Spectral data is as follows: 31P NMR (D 2O, δ: ppm, J:Hz): δ 59.66,59.10; 1H NMR (500MHz, D2O): δ 7.89,7.88 (1H, dd, 3J=5, H-6), 5.82 (2H, m, H-1 ', 5), 4.86 (2H, m, H-2 ', 3 '), 4.41 (1H, m, H-4 '), 4.04 (2H, m, H-5 '), 3.73 (3H, s, OCH 3), 3.57 (2H, m, H-α), 3.45 (1H, m, H-β), 3.21 (2H, m, H-γ), 1.31,1.30 (2H, d, 2CH 3); 13C NMR (500MHz, D 2O): δ 178.04 (COOMe), 167.55 (C-4), 152.28 (C-2), 146.36,146.32 (C-6), 107.62,107.43 (C-5), 98.76,98.41 (C-1 '), (88.23 C-4 '), 85.71,85.63 (C-2 '), 82.70, (82.58 C-3 '), 67.44 (C-5 '), 58.54 (OCH 3), 50.73 (C-α), 48.66 (C-β), 35.68 (C-γ), 22.45 (CH 3), 22.55 (CH 3); ESI-MS (pos.): m/z 468 (M+H) +ESI-MS (neg.): m/z 466 (M-H) -
The anti-HIV-1 activity experiment of this compound in cem cell and MT-4 cell
ED 50 CEM-TK- 5×10 -5M (CD 50 6×10 -4M)
CEM-SS 6×10 -5M (CD 50 4×10 -5M)
MT?4 7×10 -5M (CD 50 7×10 -5M)
Nucleoside 5 '-thiophosphoryl amino acid methyl ester be a class brand-new have an active compound of inverase, by synthetic different types of nucleosides-amino acid conjugate, and carry out activity experiment, tentatively obtain satisfied result, be further development and the development of new inverase achievement in research that provides the foundation.

Claims (4)

1, a kind of adenosine 5 '-thiophosphoryl amino acid ester compound is characterized in that, the structural formula of this compound is:
Figure 0012955500021
R is H in the said structure formula, CH 3, C 6H 5CH 2, (CH 3) 2CH 2, (CH 3) 2CHCH 2
The synthesis step of above-claimed cpd is as follows:
(1) under nitrogen protection, room temperature is dissolved in phosphorus thiochloride in the dry tetrahydrofuran (THF) of crossing, and is mixed with the solution of 1mol/L;
(2) the amino acid methyl ester hydrochloride of adding same substance amount in above-mentioned solution slowly drips acid binding agent after stirring;
(3) follow the tracks of reaction process with nuclear magnetic resonance analyser, treat that the phosphorus thiochloride total overall reaction finishes after, the adenosine that is dissolved in the dry pyridine is slowly splashed in the above-mentioned system, the back that stirs continue to drip acid binding agent;
(4) after reaction is finished, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last;
(5) after the hydrolysis fully, carry out column chromatography for separation, can obtain product of the present invention with silicagel column.
2, a kind of guanosine 5 '-thiophosphoryl amino acid ester compound is characterized in that, the structural formula of this compound is:
Figure 0012955500022
R is H in the said structure formula, CH 3, C 6H 5CH 2, (CH 3) 2CH 2, (CH 3) 2CHCH 2
The synthesis step of above-claimed cpd is:
(1) under nitrogen protection, room temperature is dissolved in phosphorus thiochloride in the dry tetrahydrofuran (THF) of crossing, and is mixed with the solution of 1mol/L;
(2) the amino acid methyl ester hydrochloride of the amount of adding same substance in above-mentioned solution slowly drips acid binding agent after stirring;
(3) use nuclear magnetic resonance analyser; Follow the tracks of reaction process, treat that the phosphorus thiochloride total overall reaction finishes after, the guanosine that is dissolved in the dry pyridine is slowly splashed in the above-mentioned system, acid binding agent is continued to drip in the back that stirs;
(4); After reaction is finished, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last;
(5) after the hydrolysis fully, carry out column chromatography for separation, can obtain product of the present invention with silicagel column.
3, a kind of cytidine 5 '-thiophosphoryl amino acid ester compound is characterized in that, the structural formula of this compound is:
Figure 0012955500031
R is H in the said structure formula, CH 3, C 6H 5CH 2, (CH 3) 2CH 2, (CH 3) 2CHCH 2
The synthesis step of above-claimed cpd is:
(1) under nitrogen protection, room temperature is dissolved in phosphorus thiochloride in the dry tetrahydrofuran (THF) of crossing, and is mixed with the solution of 1mol/L;
(2) the amino acid methyl ester hydrochloride of the amount of adding same substance in above-mentioned solution slowly drips acid binding agent after stirring;
(3) follow the tracks of reaction process with nuclear magnetic resonance analyser, treat that the phosphorus thiochloride total overall reaction finishes after, the cytidine that is dissolved in the dry pyridine is slowly splashed in the above-mentioned system, the back that stirs continue to drip acid binding agent;
(4) after reaction is finished, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last;
(5) after the hydrolysis fully, carry out column chromatography for separation, can obtain product of the present invention with silicagel column.
4, a kind of uridine 5 '-thiophosphoryl amino acid ester compound is characterized in that, the structural formula of this compound is:
R is H in the said structure formula, CH 3, C 6H 5CH 2, (CH 3) 2CH 2, (CH 3) 2CHCH 2
The synthesis step of above-claimed cpd is:
(1) under nitrogen protection, room temperature is dissolved in phosphorus thiochloride in the dry tetrahydrofuran (THF) of crossing, and is mixed with the solution of 1mol/L;
(2) the amino acid methyl ester hydrochloride of the amount of adding same substance in above-mentioned solution slowly drips acid binding agent after stirring;
(3) follow the tracks of reaction process with nuclear magnetic resonance analyser, treat that the phosphorus thiochloride total overall reaction finishes after, the uridine that is dissolved in the dry THF is slowly splashed in the above-mentioned system, the back that stirs continue to drip acid binding agent;
(4) after reaction is finished, filter, rotary distillation removes and desolvates and other low-boiling point materials, is hydrolyzed with ammoniacal liquor at last;
(5) after the hydrolysis fully, carry out column chromatography for separation, can obtain product with silicagel column;
CNB001295551A 2000-10-09 2000-10-09 Nucleoside 5'-thiophosphoryl amino-acid ester compound Expired - Fee Related CN1133642C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB001295551A CN1133642C (en) 2000-10-09 2000-10-09 Nucleoside 5'-thiophosphoryl amino-acid ester compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB001295551A CN1133642C (en) 2000-10-09 2000-10-09 Nucleoside 5'-thiophosphoryl amino-acid ester compound

Publications (2)

Publication Number Publication Date
CN1290707A true CN1290707A (en) 2001-04-11
CN1133642C CN1133642C (en) 2004-01-07

Family

ID=4593586

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB001295551A Expired - Fee Related CN1133642C (en) 2000-10-09 2000-10-09 Nucleoside 5'-thiophosphoryl amino-acid ester compound

Country Status (1)

Country Link
CN (1) CN1133642C (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012053917A1 (en) 2010-10-19 2012-04-26 Instytut Chemii Bioorganicznej Pan Nucleotide analogue, method of synthesis of nucleotide analogue, use of nucleotide analogue, antiviral pro-nucleotide, pharmaceutical composition
CN103209987A (en) * 2010-09-22 2013-07-17 艾丽奥斯生物制药有限公司 Substituted nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
CN104334570A (en) * 2012-03-21 2015-02-04 艾丽奥斯生物制药有限公司 Methods of preparing substituted nucleotide analogs
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2016184361A1 (en) * 2015-05-15 2016-11-24 上海唐润医药科技有限公司 Anti-hepatitis c virus nucleoside compound and use thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
JP6165848B2 (en) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー D-amino acid compounds for liver disease
CA2871547C (en) 2012-05-25 2021-05-25 Janssen R&D Ireland Uracyl spirooxetane nucleosides
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
AU2013329521B2 (en) 2012-10-08 2018-04-19 Centre National De La Recherche Scientifique 2'-chloro nucleoside analogs for HCV infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278990B2 (en) 2010-09-22 2016-03-08 Alios Biopharma, Inc. Substituted nucleotide analogs
CN103209987A (en) * 2010-09-22 2013-07-17 艾丽奥斯生物制药有限公司 Substituted nucleotide analogs
US8871737B2 (en) 2010-09-22 2014-10-28 Alios Biopharma, Inc. Substituted nucleotide analogs
CN103209987B (en) * 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 Substituted nucleotide analog
WO2012053917A1 (en) 2010-10-19 2012-04-26 Instytut Chemii Bioorganicznej Pan Nucleotide analogue, method of synthesis of nucleotide analogue, use of nucleotide analogue, antiviral pro-nucleotide, pharmaceutical composition
US9206209B2 (en) 2010-10-19 2015-12-08 Instytut Chemii Bioorganicznej Pan Nucleotide analogue, method of synthesis of nucleotide analogue, use of nucleotide analogue, antiviral pro-nucleotide, pharmaceutical composition
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
US9605018B2 (en) 2011-12-22 2017-03-28 Alios Biopharma, Inc. Substituted nucleotide analogs
CN104334570A (en) * 2012-03-21 2015-02-04 艾丽奥斯生物制药有限公司 Methods of preparing substituted nucleotide analogs
CN104334570B (en) * 2012-03-21 2017-06-06 艾丽奥斯生物制药有限公司 The method for preparing the nucleotide analog of substitution
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9856284B2 (en) 2012-03-21 2018-01-02 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2016184361A1 (en) * 2015-05-15 2016-11-24 上海唐润医药科技有限公司 Anti-hepatitis c virus nucleoside compound and use thereof
CN106279322A (en) * 2015-05-15 2017-01-04 上海唐润医药科技有限公司 The nucleoside compound of anti-hepatitis C virus and application thereof
CN106279322B (en) * 2015-05-15 2019-07-30 上海唐润医药科技有限公司 The nucleoside compound of anti-hepatitis C virus and its application

Also Published As

Publication number Publication date
CN1133642C (en) 2004-01-07

Similar Documents

Publication Publication Date Title
CN1133642C (en) Nucleoside 5'-thiophosphoryl amino-acid ester compound
CN1803137A (en) Process for producing crystal
CN1561331A (en) Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
CN1122036C (en) Intermediates and process for preparing olanzapine
CN1960965A (en) Synthesis of amino-alkoxy-heptanoic alkyl ester
CN1016507B (en) Forskolin derivatives
CN1231472C (en) Pyrimidine acyclonucleoside derivatives, preparation method and use thereof
CN1206212C (en) Tri-substd. phenyl derivs. and analogues
CN1108657A (en) Calanthamine derivatives, a process for their preparation and their use as medicaments
CN1097591C (en) Process for preparing pyrimidine derivatives
CN1101349A (en) Novel compounds
CN1147477C (en) Novel allylthiopyridazine derivatives and process for preparing the same
CN86106534A (en) Carbocyclic purine nucleosides, its preparation and purposes
CN1028997C (en) Anthracycline pharmaceuticals and process for preparing same
CN1133641C (en) Thiophosphamino acid ester compound containing 3'-azido-deoxythymidine and its preparing process
CN1057297C (en) Crystals of antimicrobial compound
CN1538954A (en) Protected 3,5-dihydroxy-2, 2-dimethyl-valeronitriles for synthesis of epothilones and derivatives and method for preparaton and use thereof
CN1337401A (en) Thiophosphoryl amino acid ester compound and its prepn process
CN1827605A (en) 4,4-disubstituted-3,4-dihydro-2(1H)- quinolones and synthesis process and use thereof
CN88102858A (en) The preparation method who can be used as the hydrazine derivative of hypotensive agent
CN1084175A (en) Novel phospholipid derivatives
CN1211489C (en) Method for separation extracting polyhydroxy fatty acid ester from bacterial thallus
CN1119191A (en) 15-deoxyspergualin analogs, their method of preparation and their use in therapeutics
CN1052009C (en) Platinum complex and malignant tumor treating drug containing the same
CN1105367A (en) Glucosamine derivative, process for preparing the same and synthetic intermediate thereof

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee